Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
The facility will manufacture its Herceptin biosimilar, Tuznue
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Whipple procedure is a very complex operation, mainly performed to remove pancreatic cancer
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
The drug is also intended for the treatment of glioblastoma multiforme
Subscribe To Our Newsletter & Stay Updated
